Firms with an interest in artificial intelligence (AI), such as Microsoft and Nvidia, led US stock markets to new heights last year, as investors sought to pric 15 March 2024
Pfizer has won European Commission (EC) approval for Prevenar 20 for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcu 13 March 2024
Data protection is in the spotlight in Europe, as lawmakers gather to decide on an important set of rules on intellectual property, the Regulatory Data Protecti 11 March 2024
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (D 4 March 2024
Drugmakers, patient advocate groups, policymakers and others have come together for Rare Disease Day, which took place at the end of February, to both celebrate 4 March 2024
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of the marketing authorization f 29 February 2024
Medicines for Europe, a trade group for the European generics industry, has welcomed the position adopted today by the European Parliament regarding SPC regulat 28 February 2024
Genetic disease company Vertex Pharmaceuticals has secured conditional marketing authorization for Casgevy (exagamglogene autotemcel) in Europe. 13 February 2024
The European Commission (EC) has granted marketing authorization for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) i 29 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.